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the fully adjusted HR was 2.03; 95% CI (1.13-3.65) among children exposed to SSRIs 
alone and 4.10; 95% CI (1.35-12.41) among children exposed to combined classes 
of antidepressant. ConClusions: This study suggests that use of antidepressant 
during the 2nd/3rd trimester of pregnancy may increase the risk of ASD.
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IncIdence of antIPsycHotIc PolyPHarMacy In tHe texas MedIcaId 
PoPulatIon
Desai P1, Lawson K.A.1, Richards K.1, Rascati K.L.1, Barner J.C.1, Miller A.2
1The University of Texas at Austin, Austin, TX, USA, 2University of Texas Health Science Center, 
San Antonio, TX, USA
objeCtives: To estimate the incidence of antipsychotic polypharmacy (APP) in 
the Texas Medicaid population. Methods: Adults newly initiated on antipsychot-
ics between July 1, 2006 and December 31, 2010 were followed for 365 days after 
the index antipsychotic claim. APP was defined as the concomitant use of two or 
more antipsychotics for at least 60 days without a gap in polypharmacy greater 
than 31 days. Monotherapy (MT) was defined as exposure to no more than one 
antipsychotic at a time during the one year after the index antipsychotic claim. 
Sensitivity analyses were conducted to determine how variations in the definition of 
APP impacted incidence. Results: Of the 23,232 patients meeting eligibility criteria, 
5.4% (N= 1,253) were on APP and 94.6% (N= 21,979) on MT during the study period. 
Among those on APP, 70.1% used a combination of atypicals, 1.1% used a combina-
tion of typicals, 27.7% used a combination of a typical and an atypical, 0.8% used 
clozapine and an atypical, and 0.3% used clozapine and a typical. Among those on 
MT, 7% used typicals, 92.9% used atypicals, and 0.2% used clozapine. Patients with 
APP had a mean of 106.6±94.2 (median= 86, interquartile range [IQR]= 168) days prior 
to starting polypharmacy, a mean of 141.4±77.7 (median= 118, IQR= 108) days on poly-
pharmacy, and a mean of 1.1±0.3 (median= 1, IQR= 0) APP episodes per patient. When 
the overlap period for antipsychotics was increased from 60 to 120 and 180 days, the 
incidence of APP fell from 5.4% to 2.2% and 1.3%, respectively. When the gap period 
was varied from 31 to 15 and 45 days, the incidence of APP changed from 5.4% to 
4.6% and 6.9%, respectively. ConClusions: Although no clinical guidelines support 
APP, it was still seen for some patients in the study population. Future studies should 
be conducted to evaluate the costs and outcomes associated with this practice.
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objeCtives: Depression is one of the most common disorders among the elderly 
nursing home residents. However, little is known about the demographic and 
behavioral characteristics of elderly nursing home residents with depression in the 
United States. Methods: A cross-sectional study was conducted using 2007-2008 
Minimum Data Set (MDS) linked to Medicare enrollment file to identify residents 
65 years or older with depression. Patients with full coverage for Medicare Parts 
A, B and D for the entire study period or until the date of death were included in 
the study. Descriptive statistics was performed to determine socio-demographic 
and behavioral characteristics of elderly nursing home residents with depres-
sion. Results: The national study cohort consisted of 833,453 elderly nursing home 
residents with depression. Mean age of the residents was 81.09 ± 8.23 years. Most 
of the patients were females (78.26%), Whites (85.36%), widowed (49.66%) and had 
high school education (26.22%). The majority of the residents were diagnosed with 
hypertension (88.37%), followed by anemia (70.01%), dementia (65.74%), ischemic 
heart disease (61.34%), rheumatoid arthritis (58.86%) and congestive heart failure 
(55.22%). Antidepressants (68.09%) were the most commonly used drug class fol-
lowed by diuretics (39.22%) and antipsychotics (24.79%). Among the residents with 
assessments, the mean Index of Social Engagement score (range 0-6) was 2.43 ± 
1.57. The mean Depression Rating Scale score (range 0-14) was 0.99 ± 1.59. The 
mean Aggressive Behavior Scale score (range 0-12) was 0.51 ± 1.27 in the study 
sample. ConClusions: Elderly nursing home residents with depression suffer 
from significant comorbidities. Most of these residents are managed by antide-
pressant pharmacotherapy. Further research is needed to address evidence gap 
regarding the safety and effectiveness of many medications used by the elderly 
nursing home residents.
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objeCtives: Anticholinergic medication use in elderly dementia patients is of great 
concern due to cognitive and central side-effects associated with these agents. 
Consequently, anticholinergic medications are considered inappropriate in elderly 
dementia patients. This study examined the prevalence and predictors of inappro-
priate anticholinergic medication use in elderly dementia patients using multi-year 
national survey data. Methods: The study involved a retrospective cross-sectional 
study design using 2009-2010 Medical Expenditure Panel Survey (MEPS). The study 
sample included patients aged ≥ 65 years diagnosed with dementia. Inappropriate 
anticholinergic medications were identified using the revised American Geriatrics 
Society (AGS) Beers’ criteria. Descriptive statistics using sampling weights were 
used to estimate the prevalence of inappropriate anticholinergic medication use. 
Multivariable logistic regression within the conceptual framework of Anderson 
Behavioral Model was used to identify the factors associated with inappropriate 
anticholinergic use in elderly dementia patients. Results: According to the MEPS, 
a total of 3.78 million (95% CI: 3.17-4.38) elderly patients had dementia for an overall 
prevalence of 4.81%. An estimated 1.02 million dementia patients (95% CI: 0.70-
1.3) reported use of inappropriate anticholinergic medications for a prevalence 
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objeCtives: Newer antidepressants selective serotonin reuptake inhibitors (SSRIs) 
and serotonin norepinephrine reuptake inhibitors (SNRIs) are the most commonly 
prescribed antidepressants. This is due mostly to their better side effect profile 
when compared to older drugs like tricyclic antidepressants (TCAs). However 
these classes are not completely bereft of side effects. Hyponatremia is a condition 
in which the serum sodium level falls below normal; it has been proposed this 
occurrence is associated with the binding affinity to the 5-HT receptor. The objec-
tive of our study is to compare the incidence of hyponatremia among the newer 
classes of antidepressants. Methods: We used a cohort study design using Lifelink 
claims data to compare the incidence of hyponatremia in TCAs, SSRIs, and SNRIs. 
Incidence was reported per 10,000 person-years. Cox model was used to assess 
the risk of adverse events while adjusting for potential confounders. Results: 
A total of 314,796 patients with an incident prescription for a TCA, SSRI, or SNRIs 
were identified and met study inclusion criteria. The unadjusted hazard ratio for 
hyponatremia in patients on SSRIs was 0.789 (C.I= 0.729-0.854) and on SNRIs was 
1.112 (C.I= 0.976-1.268) when compared to TCAs. However, after adjusting for covari-
ates using the Cox model the hazard ratios were found to be 1.013 (C.I= 0.934-1.099) 
for SSRIs and 1.069 (C.I= 0.937-1.221) for SNRIs again compared to TCAs. After doing 
stepwise regression to remove covariates that did not have significant effect the 
results remained similar, 1.017(C.I= 0.939-1.101) for SSRIs and 1.074 (C.I= 0.941-1.225) 
for SNRIs. ConClusions: No significant increase in the risk of hyponatremia for 
SSRIs or SNRIs over TCAs was found. The covariates we identified show significant 
interaction with hyponatremia. However, the results must be interpreted with cau-
tion as the ICD-9 code that identifies hyponatremia has been shown to have a sen-
sitivity below 30%, thus our analysis potentially excludes a large number of cases.
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objeCtives: Anticholinergic medications are extensively used in nursing homes. 
However, limited data exists regarding the utilization pattern of anticholinergic 
medications among residents with depression. The current study evaluated the 
extent of anticholinergic medication use in elderly nursing home residents with 
depression. Methods: A retrospective cross-sectional study was conducted using 
2007-2008 Medicare data from all US states. The study sample consisted of nurs-
ing home residents aged 65 years or older, who had depression. Patients with full 
coverage for Medicare Parts A, B and D and no HMO coverage for the entire study 
period or until the date of death were included in the study cohort. Anticholinergic 
medications were identified using the Anticholinergic Drug Scale (ADS), which 
classifies drugs into four categories based on their level of anticholinergic activ-
ity. Descriptive statistics was performed to determine the prevalence patterns of 
anticholinergic medication use in elderly residents with depression. Results: 
The study included 833,453 elderly residents with depression; of them, 798,880 
used anticholinergic medications for an overall prevalence of 95.85%. The highest 
prevalence was seen for level 1 anticholinergics (92.83%), followed by level 3 (45.63%) 
and level 2 drugs (27.24%). Nearly 62% of the residents used medications with sig-
nificant anticholinergic properties (level 2 or 3). Among the level 2 anticholinergics, 
the most commonly prescribed medications were quetiapine (12.68%), paroxetine 
(8.38%), cyclobenzaprine (4.49%), solifenacin (2.55%) and darifenacin (2.14%). The 
most frequently prescribed level 3 anticholinergics were promethazine (13.08%), 
tolterodine (8.06%), oxybutynin (6.95%), olanzapine (6.67%), hydroxyzine (6.24%), 
meclizine (5.86%) and amitriptyline (3.86%). ConClusions: The study found that, 
over 6 in10 elderly nursing home residents with depression used medications with 
significant anticholinergic properties. In light of significant central and peripheral 
adverse effects of these agents, there is a need to optimize the use of anticholinergic 
medications among the elderly residents with depression.
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objeCtives: To our knowledge, four studies have attempted to investigate the asso-
ciation between gestational maternal use of antidepressant and risk of Autism 
Spectrum Disorder (ASD). However, several methodological drawbacks remain in 
these studies. We sought to assess the impact of gestational antidepressant use 
on the risk of (ASD) in children, controlling adequately for potential confounding 
factors. Methods: A large population-based cohort study including all singletons 
at term live births during 1998-2009 was conducted using data from the Quebec 
Pregnancy Cohort. Antidepressant exposure during pregnancy was defined accord-
ing to trimester of use and specific classes. Events were infants having diagnosis of 
ASD before December 31st, 2009. We used a survival analysis to estimate crude and 
adjusted hazards ratio (HRs) with 95% confidence intervals by means Cox propor-
tional hazards regression. Results: of 145 456 children born from 1998 through 
2009, 1 045 (0.67%) were identified with ASD. The mean age of the children at the 
end of follow up was 6.24 ±3.19 (median, 7.00). We identified 4 724 (3.24%) children 
exposed to antidepressant during overall pregnancy and 9 207 (6.32%) children 
exposed one year prior pregnancy. Among 4 724 children exposed to antidepres-
sant during pregnancy, 4 200 (2.88%) were exposed during first trimester and 2 532 
(1.74%) were exposed during 2nd/3rd trimester. We found only exposure to any anti-
depressant during 2nd/3rd trimester was associated with significantly increased risk 
of ASD (aHR= 1.81; 95% CI (1.12-2.93)). When compared the risk of ASD for different 
classes of antidepressant use during 2nd/3rdwith unexposed to any antidepressant, 
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cohort study, with assessments of clinical outcomes every 6 months. Remission 
was defined as a mild or lower level on 8 key items of Positive And Negative 
Symptoms Scale (PANSS) - P1, P2, P3, N1, N4, N6, G5 and G9 - for at least 6 months. 
Symptomatic remission was described at each visit. Bivariate analyses were 
then conducted to compare groups in terms of symptoms severity, functioning, 
quality of life and economic burden. A repeated logistic model was finally used 
to identify risk factors associated with symptomatic remission. Results: The 
proportion of patients achieving symptomatic remission within 2 years was 36%. 
This outcome was found to be stable over time: 72% of patients achieving symp-
tomatic remission at any visit remained in remission at the next visit. Significant 
differences were found between groups in terms of severity (p < 0.0001), function-
ing (p < 0.0001), quality of life (p < 0.0001) and most of the resource use compo-
nents (p < 0.0001). Factors associated with remission included baseline depression 
level (p= 0.005), baseline severity of symptoms (p < 0.0001), baseline functioning 
(p < 0.0001), and compliance level (p < 0.0001). ConClusions: This research 
indicates that patients in symptomatic remission have better social function-
ing, better quality of life and lower resource use than other patients. Achieving 
symptomatic remission should be an important treatment goal in the treatment 
of schizophrenia.
Mental HealtH – cost studies
PMH24
analysIs PersPectIve for assessIng tHe fInancIal IMPact of 
InterventIons used In rural/reMote settIngs – a canadIan case 
study of foMePIzole for toxIc alcoHol PoIsonIng
Budden A.J.1, Lee K.M.2
1Canadian Agency for Drugs and Technologies in Health, Ottawa, ON, Canada, 2Canadian Agency 
for Drugs and Technologies in Health (CADTH), Ottawa, ON, Canada
objeCtives: To assess the implications of conducting budget impact analyses 
from different perspectives when evaluating interventions used in remote/rural 
settings. In the case study, fomepizole vs. ethanol for methanol/ethylene glycol 
poisoning was assessed from perspectives of remote nursing stations and the 
health care system in Canada. Methods: Literature searches were undertaken 
to obtain cost and health care resource use information. Experts from Health 
Canada and the Alberta Poison and Drug Information Service were consulted to 
provide additional information and assist with interpretation and applicability of 
data. Results: From the perspective of the remote nursing station, fomepizole 
appears to be a more costly treatment than ethanol. However, this perspective 
only takes into account drug costs, nursing costs and transportation costs. Remote 
nursing stations cannot effectively monitor ethanol levels to ensure correct dosing 
without access to labs – fomepizole does not require dose monitoring; potentially 
impacting patient’s health. Where transfer to a tertiary care facility is delayed, 
continued treatment without lab monitoring may increase the likelihood of com-
plications from ethanol treatment, or methanol or ethylene glycol poisoning, lead-
ing to downstream health care resource use at tertiary care facilities (need for 
ICU, increased LOS), as well as impacting patient quality of life. ConClusions: 
Fomepizole is a costly treatment that reduces the burden on staff and may lead 
to improved outcomes for patients in the tertiary care setting. However, given 
that rural/remote nursing stations have to manage their own budgets, fomepizole 
may not be considered cost-effective compared to other treatment options when 
only considering the short time frame the patient is in their care (until transfer to 
tertiary care facility). Based on a broader perspective (health care payer or patient), 
implications beyond the budget may be relevant and as such, an economic evalua-
tion of fomepizole from a broader perspective would provide valuable information 
to the Canadian health care system.
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MedIcaId PoPulatIon budget IMPact analysIs of buPrenorPHIne/
naloxone fIlM and tablet forMulatIon
Clay E.1, Kharitonova E.1, Ruby J.2, Aballéa S.1, Zah V.3
1Creativ-Ceutical, Paris, France, 2Reckitt Benckiser Pharmaceuticals, Inc./NA, Richmond, VA, USA, 
3ZRx Outcomes Research Inc., Mississauga, ON, Canada
objeCtives: Buprenorphine/naloxone (BUP/NAL) for the treatment of opioid 
dependence combination is available in film (since September 2010) and tablet 
formulation. Earlier studies showed that treatment with BUP/NAL film formu-
lation leads to an improved treatment persistence and lower health care costs 
compared to BUP/NAL tablet formulation. A budget impact analysis was built to 
assess the health care expenditures related to new patients entering treatment in 
scenarios characterized by different market shares of the two BUP/NAL formula-
tions. Methods: A Markov model was structured tracking a cohort of patients 
initiating opioid dependence treatment with BUP/NAL film or BUP/NAL tablet 
formulation through successive phases of treatment: initiation, maintenance, dis-
continuation, off treatment and reinitiation. Transition probabilities and resource 
utilization were estimated from a Marketscan Multi-State Medicaid database. The 
total health care expenditure over five years was predicted for 65.6 million mem-
bers for the following scenarios: 1) 100% market share BUP/NAL film formulation, 
2) 100% market share BUP/NAL tablet formulation broken between all BUP/NAL 
tablet formulations currently available in the market. Results: In the first year, 
for Scenario 1 (100% on BUP/NAL Film) costs of medication acquisition were found 
to be %6.1 (-US$18.1 million) lower. Costs of outpatient care were 31.65% (US$110.6 
million) higher. Nevertheless, this difference was outweighed by lower costs of 
inpatient care (-36.09%) (-US$129.9 million), and emergency room (-7.96%) (-US$3.3 
million). Scenario 1 total health care costs were 4.2% and 9.4% lower in the first 
year and cumulatively over five years, respectively. ConClusions: Treatment 
with buprenorphine/naloxone film results in less health care resource utilization 
and lower total cost burden for Medicaid plans when compared to treatment with 
buprenorphine/naloxone tablet
of 26.95%. The most frequently prescribed drugs were oxybutynin (4.54%), solif-
enacin (4.48%), paroxetine (2.81%), tolterodine (2.47%) and promethazine (2.41%). 
Multivariable analysis revealed that fair/poor general health status (Odds Ratio, OR: 
5.09; 95% CI: 1.36-19.08), anxiety (OR: 3.02; 95% CI: 1.21-7.54) and mood disorder (OR: 
4.15; 95% CI: 1.87-9.22) increased the likelihood of receiving inappropriate anticho-
linergic medications, whereas age between 75 to 84 years (OR: 0.35; 95% CI: 0.15-0.81) 
decreased the likelihood of receiving inappropriate anticholinergic medications in 
elderly dementia patients. ConClusions: The study found that approximately one 
in four elderly patients with dementia used inappropriate anticholinergic medica-
tions. Given the significant cognitive effects of anticholinergic medications, there 
is an urgent need to monitor and optimize the use of anticholinergic medications 
in this vulnerable elderly population.
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Pattern and PredIctors of aMbulatory care vIsIts for substance 
use dIsorder (sud) In adolescents and young adults
Medhekar R.A., Chen H.
University of Houston, Houston, TX, USA
objeCtives: To determine the pattern and predictors of ambulatory care visits 
for Substance Use Disorder (SUD) in adolescents and young adults. Methods: A 
retrospective cross-sectional study was conducted using the 2008-2010 National 
Ambulatory Medical Care Survey (NAMCS) data. Annual visits for SUD were esti-
mated using the ICD-9CM codes 303-305; descriptive statistics were performed on 
the weighted sample. Logistic regression was used to determine the predictors of 
SUD visits identified based on previous literature. Adolescents and young adults 
were defined as individuals 12-25 years of age. Results: An estimated 23.45 mil-
lion patient visits were attributable to SUD during 2008-2010. About 15.47% of these 
visits were by adolescents and young adults. Majority of these visits were by male 
(65.21%), white (89.33%), and had comorbid anxiety (23.43%), or bipolar disorder 
(29.78%). The probability of SUD related visit decreased by 5.3% [OR= 0.947, CI-0.939-
0.955] with each year increase in age. Males had twice the odds of SUD visit than 
females [OR= 2.193, CI-1.285-3.742]. No racial differences were found, although lit-
erature suggests racial variation in SUD. Likelihood of SUD visit was 72% lower 
[OR= 0.281, CI-0.129-0.615] in the West than in the Midwest. Literature suggests 
strong association between SUD and psychiatric comorbidities. The present study 
specifically found that comorbid anxiety or bipolar disorder increased the odds of 
SUD visits by 5.2 [OR= 5.220, CI-2.616-10.414] and 16.6 [OR= 16.625, CI-5.871-47.076] 
times respectively. Significant associations were observed between SUD visits and 
psychiatric co-medications. Patients receiving prescription for Alpha-2 agonists and 
mood-stabilizers had 10 [OR= 10.122, CI-1.618-63.323] and 2.4 [OR= 2.420, CI-1.085-
5.400] times higher odds of SUD visits respectively while receiving anxiolytics had 
an opposite effect [OR= 0.454, CI-0.208-0.989]. ConClusions: The findings of the 
study are in congruence with previous literature using adult samples. Study suggests 
early onset of SUD in children and adolescents with higher visit rates in patients 
with mood or anxiety disorders.
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objeCtives: Depressive symptoms are frequent clinical features in patients with 
schizophrenia. They contribute substantially to the burden of disease, and are 
associated with exacerbations of deficits in psychosocial functioning. The objec-
tive of this study was to describe prevalence and key risk factors associated with 
depressive symptoms, using data from a longitudinal cohort study. Methods: 
We used data from EuroSC, a multicenter 2-year cohort study conducted in France, 
England and Germany. The Calgary Depression Scale for Schizophrenia (CDSS), 
developed to assess the level of depressive symptoms in schizophrenia, was com-
pleted every 6 months, as well as other clinical outcomes (severity of symptoms, 
functioning, etc.) and quality of life. First, prevalence of depressive symptoms was 
described using several CDSS cut-offs. Correlations with other negative symptoms 
measures were also described. Then bivariate analyses were conducted to describe 
clinical outcomes and quality of life among patients with and without depressive 
symptoms. Finally, a repeated logistic model was implemented to identify key 
factors associated with depressive symptoms. Results: Our sample consisted in 
1208 patients with schizophrenia. The mean CDSS score at baseline was 0.93 (1.22). 
Prevalence of depressive symptoms ranged from 5% to 27.6% depending on CDSS 
cut-off used. Correlations with negative symptoms measures were all significant. 
Bivariate analyses suggested a higher clinical burden and a decreased quality of 
life for depressive patients. The multivariate model identified functioning, men-
tal composite score of SF36 and non-compliance level as key factors associated 
with depressive symptoms. ConClusions: This study shows that depressive 
symptoms associated with the antipsychotics have a significant impact on clini-
cal outcomes and quality of life, independently of the CDSS cut-off used. Key 
factors associated with depressive symptoms are functioning, quality of life and 
non-compliance.
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objeCtives: The typical course of schizophrenia starts with a premorbid phase, 
followed by a phase of symptomatic but unrecognised/treated disease, and 
acute exacerbations with more or less partial remission phases in between. The 
objective of this study is to describe patients with symptomatic remission in an 
observational longitudinal study of patients with schizophrenia, and to identify 
potential risk factors. Methods: We used data from EuroSC, a European 2-year 
